相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
33.3%
尚未招募
1
33.3%
招募中
1
33.3%
暂无批准数据
- Cellectis' board approved a strategic transformation on September 11, 2026, ending internal development of CAR-T candidates lasme-cel and eti-cel and refocusing on in vivo gene editing. - The company will advance two preclinical programs, .HEAL-101 targeting APOC3 for severe hypertriglyceridemia and .HEAL-201 targeting PCSK9 for severe hypercholesterolemia, both LNP-delivered. - Cellectis attributed the CAR-T exit to improved frontline regimens, bispecific antibody competition and slower enrollment, and will seek partners for the discontinued assets. - The operational realignment is designed to extend the cash runway into H2 2028, with preliminary Phase 1 data from .HEAL-101 expected in H2 2027 and .HEAL-201 in H1 2028.
- A new market report forecasts continued expansion of the global CD70-targeting therapies pipeline across the United States, China, and Europe as candidates advance through clinical trials and regulatory review. - Clinical development increasingly incorporates combination regimens pairing CD70 therapies with immunotherapies, epigenetic inhibitors, chemotherapy, and targeted agents to strengthen responses and address resistance. - Leading companies including Allogene Therapeutics, Ambrx (Johnson & Johnson), Molecular Partners, and CRISPR Therapeutics are advancing differentiated programs through proprietary platforms such as allogeneic cell therapy and DARPin engineering. - The report highlights biomarker-driven development and patient-selection strategies as key levers for more precise clinical positioning across leukemia, lymphoma, renal cell carcinoma, and autoimmune indications.
- Casgevy (exagamglogene autotemcel), developed by CRISPR Therapeutics and Vertex Pharmaceuticals, is the first regulatory-approved cell-based gene therapy for sickle cell disease and beta-thalassemia. - The therapy leverages CRISPR/Cas9 gene-editing technology to deliver a potentially curative, one-time treatment for these inherited blood disorders. - CRISPR Therapeutics reported modest revenue of $11.6 million in the first half of 2026 and a net loss of $214 million, reflecting the high-risk, high-reward nature of gene-editing development. - The company's pipeline extends beyond hemoglobinopathies to include in vivo approaches and regenerative medicine programs.
- CRISPR Therapeutics' Casgevy receives FDA approval for pediatric use, significantly broadening the addressable patient population for the gene-editing therapy. - The company currently trades at $56.34 with a consensus analyst price target of $74.50, suggesting substantial upside despite negative profitability metrics. - CRISPR Therapeutics faces ongoing challenges including a gross profit margin of -20.092% and persistent cash burn as it works to commercialize its gene-editing platform. - The approval marks a critical milestone for CRISPR-based therapies, though execution risks and high valuation relative to current earnings remain key investor concerns.
- The global gene editing therapeutics market is projected to grow at a compound annual growth rate of 12.5%, fueled by expanding clinical applications and rising disease burden. - CRISPR-based technologies dominate the market due to their efficiency and cost-effectiveness, while oncology represents the largest therapeutic application segment. - High development costs, regulatory complexity, and off-target safety concerns remain significant barriers to broader adoption and commercialization. - Key players including CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, and Beam Therapeutics are driving innovation through partnerships and investments in next-generation editing platforms.
- A major international consortium has proposed harmonized standards and resources to accelerate the clinical adoption of medical genome sequencing. - The framework addresses critical gaps in data interoperability, variant interpretation, and resource sharing that currently limit genomic medicine's clinical impact. - Key opinion leaders from academia, industry, and regulatory bodies contributed to the consensus, published in Nature. - The initiative aims to establish unified benchmarks that could transform how genomic data is integrated into routine patient care.
- Gene therapy developers are increasingly exploring non-viral delivery methods following safety concerns with viral vectors, including patient deaths linked to liver toxicity in studies by Sarepta, Pfizer, Intellia, Rocket, and Capsida. - Lipid nanoparticles (LNPs), Sleeping Beauty transposon systems, and electro-transfection are emerging as promising non-viral alternatives that may offer improved safety profiles and reduced manufacturing complexity. - While experts view non-viral approaches as potentially representing the future of gene therapy, they expect these methods to coexist with viral vectors rather than completely replace them in the near term. - Non-viral systems offer advantages including greater payload flexibility, potentially lower manufacturing costs, and reduced immunogenicity risks, though further clinical validation is needed to realize their full potential.
- Alloy Therapeutics appointed Christian Cobaugh, Ph.D., as CEO of its Genetic Medicines division to lead development of AntiClastic nucleic acid medicines targeting diseases at the genetic level. - The proprietary AntiClastic cyclic nucleic acid technology demonstrates improved potency and reduced inflammatory responses compared to traditional antisense oligonucleotides and siRNA formats. - Cobaugh brings over 15 years of genetic medicines leadership experience, including roles at CRISPR Therapeutics, Arcturus Therapeutics, and as founding CEO of Vernal Biosciences. - The AntiClastic platform integrates AI-based sequence design with validated oligonucleotide synthesis to advance partnered programs from therapeutic concepts to development candidates.
- CRISPR Therapeutics' zugo-cel CAR-T therapy demonstrated significant clinical improvement in four autoimmune patients, with one systemic lupus erythematosus patient achieving drug-free remission through six months. - The therapy showed a 90% overall response rate and 70% complete response rate in relapsed/refractory large B-cell lymphoma patients at the 600 million cell dose level. - The company initiated a new Phase 1 trial for immune thrombocytopenic purpura and warm autoimmune hemolytic anemia, and established a collaboration with Lilly to evaluate combination therapy. - Treatment was well-tolerated across indications with no high-grade cytokine release syndrome or neurotoxicity observed at the 100 million cell dose used in autoimmune trials.
- Stanford researchers achieved complete diabetes reversal in mice using combined blood stem cell and islet transplants that eliminate the need for insulin or immunosuppressive drugs. - Vertex Pharmaceuticals presented first-ever clinical data on CASGEVY gene therapy in children ages 5-11 with sickle cell disease, showing all patients achieved freedom from vaso-occlusive crises for at least 12 months. - Novo Nordisk filed for FDA approval of higher-dose Wegovy 7.2 mg, which achieved 20.7% average weight loss compared to 17.5% with the current approved dose in Phase 3 trials. - The U.S. diabetes market is projected to surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care.
